Share:
Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales
Faran to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greece
PARIS and NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE)
Quantum Genomics
(Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Faran to develop and commercialize firibastat in Greece. This new agreement is the first step of Quantum Genomics partnering strategy in Europe.
QUANTUM GENOMICS: Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran
Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales
Faran to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greece
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Faran to develop and commercialize firibastat in